Insight Molecular Diagnostics Inc. Common Stock IMDX
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $10.50 (+144.2% upside)
Key Stats
- Today's Range
- $4.20 – $4.43
- 50-Day Range
- $3.54 – $6.19
- 52-Week Range
- $2.33 – $8.51
- Volume
- 112K shs
- Average Volume
- 214K shs
- Market Cap
- $143.33 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.93%
- Days to Cover
- 1.16
About Insight Molecular Diagnostics Inc. Common Stock
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Related Stocks
Compare head-to-head: IMDX vs IDXX·IMDX vs LNTH·IMDX vs CLDX·IMDX vs NTLA
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.